Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $226.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective upped by research analysts at Barclays from $185.00 to $226.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price indicates a potential upside of 40.62% from the stock’s current price.

Other analysts have also recently issued reports about the company. Robert W. Baird boosted their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 4th. UBS Group boosted their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Citigroup upped their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, Bank of America upped their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $177.65.

Sarepta Therapeutics Stock Up 30.1 %

Sarepta Therapeutics stock opened at $160.72 on Friday. The stock has a market capitalization of $15.19 billion, a PE ratio of 1,461.09 and a beta of 0.96. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $173.25. The business has a 50 day simple moving average of $125.56 and a 200-day simple moving average of $119.95. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business’s revenue was up 63.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.44) earnings per share. On average, analysts anticipate that Sarepta Therapeutics will post 2.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of SRPT. Capital Fund Management S.A. purchased a new position in Sarepta Therapeutics during the fourth quarter worth $7,299,000. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 0.5% during the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after buying an additional 41,465 shares in the last quarter. Principal Financial Group Inc. increased its position in Sarepta Therapeutics by 125.3% during the fourth quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after buying an additional 27,549 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in Sarepta Therapeutics during the fourth quarter worth $777,000. Finally, Great Point Partners LLC increased its position in Sarepta Therapeutics by 14.0% during the fourth quarter. Great Point Partners LLC now owns 80,000 shares of the biotechnology company’s stock worth $7,714,000 after buying an additional 9,800 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.